- The most common ADRs seen with KADCYLA in EMILIA (frequency > 25%) were nausea, fatigue, musculoskeletal pain, thrombocytopenia, increased transaminases, headache, and constipation. The most common NCI-CTCAE (version 3) ≥ Grade 3 ADRs (frequency > 2%) were thrombocytopenia, increased transaminases, anemia, hypokalemia, peripheral neuropathy and fatigue

You are encouraged to report side effects to Genentech and the FDA. You may contact Genentech by calling **1 (888) 835-2555**. You may contact the FDA by visiting **www.fda.gov/medwatch** or calling **1 (800) FDA-1088**.

Please see accompanying full Prescribing Information for additional important safety information, including Boxed WARNINGS.

References: 1. KADCYLA Prescribing Information. Genentech, Inc. May 2013. **2.** Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hassmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. *Cancer Res.* 2009;69:9330-9336.

PATHWAYS

2

Updated video - TDM0001424701

Proposed MOA



SELECT A VIDEO

Animated MOA



MOA Video with Audio